BioCentury | Feb 27, 2021
Deals

Feb. 26 Quick Takes: Venrock leads Artiva’s crossover-laden $120M series B; plus Roivant-Silicon, Origin, Sino-Akeso, Tricida, LISCure

...Inc. (HKEX:9926) plus chemotherapy met the primary endpoint for first-line squamous non-small cell lung cancer.FDA denies Tricida...
...VCs and KOSDAQ-listed companies.TARGETSPD-1 (PDCD1; CD279) - Programmed cell death 1 Jeff Cranmer Venrock Artiva Biotherapeutics Roivant Sciences Silicon Therapeutics BridgeBio Pharma Tricida LISCure...
BioCentury | Oct 31, 2020
Product Development

Oct. 30 Quick Takes: Aducanumab heads to EMA; plus Boehringer, Arcus-AZ, Tricida

...checkpoint targets, into a late-stage PD-1/PD-L1 combination study.Tricida cuts staff with accelerated approval for veverimer ‘unlikely’Tricida Inc....
...company, the agency also would require data on renal disease progression to support accelerated approval. Tricida...
...– Transient receptor potential cation channel subfamily C member 6 BC Staff aducanumab (BIIB037) Eisai Co. Ltd. Boehringer Ingelheim Arcus Biosciences Tricida BI...
BioCentury | Aug 25, 2020
Product Development

Aug. 24 Quick Takes: Setbacks for Novartis, Odonate, Onconova, Tricida; plus upcoming adcomm for Alkermes, and Sinopharm’s vaccine

...overall survival of 6.4 months, compared with 6.3 months for physician’s choice treatment (p=0.33).FDA rebuffs Tricida’s...
...and “the demonstrated effect size would be reasonably likely to predict clinical benefit.” Shares of Tricida fell...
...sodium (ON 01910.Na, estybon, iv rigosertib) veverimer (TRC101) samidorphan/olanzapine (ALKS 3831) China National Biotech Group (Sinopharm)-COVID-19-unknown Novartis AG Odonate Therapeutics Inc. Tricida Inc. Alkermes...
BioCentury | Mar 12, 2020
Management Tracks

Hoerr takes helm from Menichella at CureVac; plus Genmab hires Mancini as COO, Tricida, Akcea, Refuge, Adaptate, Thermo Fisher and more

...of the U.S. innovative medicines unit of Bristol Myers Squibb Co. (NYSE:BMY). Renal disease play Tricida Inc....
...promoted Bobbi Coffin to chief growth officer from chief marketing officer. Robin Sawka, BioCentury Staff BioCentury Staff Genmab A/S Tricida Inc. Akcea...
BioCentury | Dec 4, 2019
Company News

Management tracks: Mittal to succeed Biocon’s Chandavarkar; plus Intercept, Nektar, Agios, Accelerate, ABPI and more

...of Caraway; he co-founded the company and will remain on the board. Renal disease play Tricida Inc....
...Hongjiang Li, Staff Writers Xenikos B.V. Alligator Bioscience AB Biocon Ltd. Intercept Pharmaceuticals Inc. Nektar Therapeutics Agios Pharmaceuticals Inc. Accelerate Diagnostics Inc. Rheostat Therapeutics Tricida Inc. Revance...
BioCentury | Nov 19, 2019
Company News

Nov. 18 Company Quick Takes: Eidos spikes on latest amyloidosis readout; plus Janssen, Pfizer, Tricida, BMS-Celgene

...U.S. as early as November 20, 2023; Pfizer plans to launch the drug that year. Tricida’s...
...Priority Review FDA accepted and granted Priority Review to an NDA for veverimer (TRC101) from Tricida Inc....
...to anti-inflammatory franchise" ). BioCentury Staff Canaglu, Invokana, canagliflozin (JNJ-28431754, TA-7284) Humira, adalimumab (D2E7) Otezla, apremilast (CC-10004) Janssen Johnson & Johnson Pfizer Inc. Tricida Inc. Bristol-Myers...
BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

...A) 4/9/19 $10.0 NA $10.6 NA Sangamo Therapeutics Inc. (NASDAQ:SGMO) 4/7/19 $145.5 $1,321.6 $1,242.4 -6% Tricida Inc....
BioCentury | Jun 29, 2019
Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

...NEEQ:430187) Vocimagene amiretrorepvec/extended release flucytosine Treat recurrent high-grade glioma Phase III final data YE19 Tricida Inc....
BioCentury | Apr 6, 2019
Finance

Room to rally in 2Q

...new listing, from NGM, and $398.5 million raised across three follow-ons from Sangamo Therapeutics Inc., Tricida Inc....
...NGM282, is due to begin Phase IIb testing in mid-2019 to treat NASH. Sangamo and Tricida...
BioCentury | Apr 4, 2019
Financial News

Follow-on roundup: Sangamo, Tricida, DBV

...Sangamo and Tricida each priced follow-ons soon after their share prices spiked on recent clinical readouts...
...I/II Readout for Hemophilia A Gene Therapy" ). Sangamo lost $0.89 to $12.14 on Thursday. Tricida Inc....
...GI tract (see "Tricida Gains on Long-Term Phase III Data for Metabolic Acidosis Therapy" ). Tricida...
Items per page:
1 - 10 of 30
BioCentury | Feb 27, 2021
Deals

Feb. 26 Quick Takes: Venrock leads Artiva’s crossover-laden $120M series B; plus Roivant-Silicon, Origin, Sino-Akeso, Tricida, LISCure

...Inc. (HKEX:9926) plus chemotherapy met the primary endpoint for first-line squamous non-small cell lung cancer.FDA denies Tricida...
...VCs and KOSDAQ-listed companies.TARGETSPD-1 (PDCD1; CD279) - Programmed cell death 1 Jeff Cranmer Venrock Artiva Biotherapeutics Roivant Sciences Silicon Therapeutics BridgeBio Pharma Tricida LISCure...
BioCentury | Oct 31, 2020
Product Development

Oct. 30 Quick Takes: Aducanumab heads to EMA; plus Boehringer, Arcus-AZ, Tricida

...checkpoint targets, into a late-stage PD-1/PD-L1 combination study.Tricida cuts staff with accelerated approval for veverimer ‘unlikely’Tricida Inc....
...company, the agency also would require data on renal disease progression to support accelerated approval. Tricida...
...– Transient receptor potential cation channel subfamily C member 6 BC Staff aducanumab (BIIB037) Eisai Co. Ltd. Boehringer Ingelheim Arcus Biosciences Tricida BI...
BioCentury | Aug 25, 2020
Product Development

Aug. 24 Quick Takes: Setbacks for Novartis, Odonate, Onconova, Tricida; plus upcoming adcomm for Alkermes, and Sinopharm’s vaccine

...overall survival of 6.4 months, compared with 6.3 months for physician’s choice treatment (p=0.33).FDA rebuffs Tricida’s...
...and “the demonstrated effect size would be reasonably likely to predict clinical benefit.” Shares of Tricida fell...
...sodium (ON 01910.Na, estybon, iv rigosertib) veverimer (TRC101) samidorphan/olanzapine (ALKS 3831) China National Biotech Group (Sinopharm)-COVID-19-unknown Novartis AG Odonate Therapeutics Inc. Tricida Inc. Alkermes...
BioCentury | Mar 12, 2020
Management Tracks

Hoerr takes helm from Menichella at CureVac; plus Genmab hires Mancini as COO, Tricida, Akcea, Refuge, Adaptate, Thermo Fisher and more

...of the U.S. innovative medicines unit of Bristol Myers Squibb Co. (NYSE:BMY). Renal disease play Tricida Inc....
...promoted Bobbi Coffin to chief growth officer from chief marketing officer. Robin Sawka, BioCentury Staff BioCentury Staff Genmab A/S Tricida Inc. Akcea...
BioCentury | Dec 4, 2019
Company News

Management tracks: Mittal to succeed Biocon’s Chandavarkar; plus Intercept, Nektar, Agios, Accelerate, ABPI and more

...of Caraway; he co-founded the company and will remain on the board. Renal disease play Tricida Inc....
...Hongjiang Li, Staff Writers Xenikos B.V. Alligator Bioscience AB Biocon Ltd. Intercept Pharmaceuticals Inc. Nektar Therapeutics Agios Pharmaceuticals Inc. Accelerate Diagnostics Inc. Rheostat Therapeutics Tricida Inc. Revance...
BioCentury | Nov 19, 2019
Company News

Nov. 18 Company Quick Takes: Eidos spikes on latest amyloidosis readout; plus Janssen, Pfizer, Tricida, BMS-Celgene

...U.S. as early as November 20, 2023; Pfizer plans to launch the drug that year. Tricida’s...
...Priority Review FDA accepted and granted Priority Review to an NDA for veverimer (TRC101) from Tricida Inc....
...to anti-inflammatory franchise" ). BioCentury Staff Canaglu, Invokana, canagliflozin (JNJ-28431754, TA-7284) Humira, adalimumab (D2E7) Otezla, apremilast (CC-10004) Janssen Johnson & Johnson Pfizer Inc. Tricida Inc. Bristol-Myers...
BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

...A) 4/9/19 $10.0 NA $10.6 NA Sangamo Therapeutics Inc. (NASDAQ:SGMO) 4/7/19 $145.5 $1,321.6 $1,242.4 -6% Tricida Inc....
BioCentury | Jun 29, 2019
Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

...NEEQ:430187) Vocimagene amiretrorepvec/extended release flucytosine Treat recurrent high-grade glioma Phase III final data YE19 Tricida Inc....
BioCentury | Apr 6, 2019
Finance

Room to rally in 2Q

...new listing, from NGM, and $398.5 million raised across three follow-ons from Sangamo Therapeutics Inc., Tricida Inc....
...NGM282, is due to begin Phase IIb testing in mid-2019 to treat NASH. Sangamo and Tricida...
BioCentury | Apr 4, 2019
Financial News

Follow-on roundup: Sangamo, Tricida, DBV

...Sangamo and Tricida each priced follow-ons soon after their share prices spiked on recent clinical readouts...
...I/II Readout for Hemophilia A Gene Therapy" ). Sangamo lost $0.89 to $12.14 on Thursday. Tricida Inc....
...GI tract (see "Tricida Gains on Long-Term Phase III Data for Metabolic Acidosis Therapy" ). Tricida...
Items per page:
1 - 10 of 30